Biohit Oyj, Stock Exchange Release, 20 November 2026 at 2:00 pm (EET)
Biohit Oyj’s Financial Reporting and Annual General Meeting in 2027
Biohit Oyj’s planned release schedule for financial reports in 2027 is as follows:
- Financial Statement Release for 2026 on Wednesday 10 February 2027 at 9:30 am.
- The Annual Report for 2026, including the financial statements and the Board of Directors’ report, on Thursday 18 March 2027 at 9:30 am.
- Half-year financial report for January–June 2027 on Wednesday 4 August 2027 at 9:30 am.
Biohit observes a silent period of 30 days before results are published. During this period, Biohit’s management and other personnel do not comment on the company’s financial position or market conditions or meet with representatives of the capital markets or financial media.
The published financial reports and other stock exchange releases are available on Biohit's website at: https://investors.biohithealthcare.com/en/.
You can also subscribe to receive releases by email using the form on Biohit’s website at: https://investors.biohithealthcare.com/en/releases/subscribe.
Biohit Oyj’s Annual General Meeting is scheduled for Wednesday 2 June 2027 at 2:00 pm. The Board of Directors will convene the meeting at a later date.
Additional information:
Jussi Hahtela, CEO, Biohit Oyj
tel. +358 50 383 5948
investor.relations@biohit.fi
www.biohithealthcare.com
Biohit in brief
Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit’s Series B shares (BIOBV) are listed on Nasdaq Helsinki in the Small Cap/Healthcare segment.